RecruitingPhase 1NCT06977126

Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers

First-in Human Clinical Trial Assessing Porphysome Nanoparticles for Biodistribution and Safety, in Imaging of Advanced Metastatic Gynaecological Cancers

Sponsor

University Health Network, Toronto

Enrollment

24 participants

Start Date

Nov 18, 2025

Study Type

INTERVENTIONAL

Conditions

Gynecological Cancers

Summary

This is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle suspension) and 64Cu-PORPHYSOMES (64Cu-PS, pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension) for PET/CT imaging assessments in patients with metastatic/advanced gynecological tumors.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 64Cu-PORPHYSOMES and a drug called PORPHYSOMES for people with gynecological cancers. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.